Apple BCI Protocols Boost Synchron

Apple turning BCI into a native input layer matters because it shifts the bottleneck from building a one off demo to plugging into the same operating system behaviors that already run iPhone and iPad accessibility. For Synchron, that means its implant is not just sending custom commands to a separate app. It can map thought driven intent into standard device navigation, which makes the product more useful in daily life and harder for hardware only rivals to match.

• Synchron’s system already works like a full stack product. The implant captures motor intent, a chest mounted transmitter and external processor decode it, then Bluetooth links that output to phones, tablets, and smart home systems. Apple support extends that chain into native control rather than a custom overlay.
  1 sacra 2 sacra
• This favors Synchron’s lower friction clinical path. Its Stentrode is placed through the jugular vein with standard catheter tools and patients are usually discharged within 1 to 2 days. That is a very different rollout model from Neuralink, which pairs higher bandwidth with craniotomy and surgical robotics.
  2 sacra 5 sacra
• Apple’s May 13, 2025 accessibility update added a new protocol for Switch Control for BCIs across iOS, iPadOS, and visionOS, and Synchron said it would be the first company to ship against that BCI HID profile. By August 2025, Synchron publicly showed a participant navigating an iPad home screen and composing text using thought alone.
  3 apple 4 businesswire

The next phase is a platform race. As Apple, Vision Pro, Alexa, and AI integrations become real product surfaces, BCI companies that can combine implantation, decoding software, and device level interoperability should capture more of the value than teams selling electrodes alone. Synchron is early on that path, and Apple’s protocol gives it a distribution template others will now have to follow.